Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab for Giant Cell Arteritis (THEIA)
NCT04633447Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of guselkumab in giant cell arteritis (GCA), sponsored by Janssen Pharmaceutical. Started Dec 2020; status: terminated.
02
Drugs
guselkumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT04633447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633447.